[8-K] Silence Therapeutics plc Reports Material Event

Rhea-AI Filing Summary

Silence Therapeutics plc reported a clinical milestone under Other Events: it has completed enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV).

The company furnished a press release as Exhibit 99.1. The information, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.

Insights

Biopharma clinical development analyst

Enrollment completion marks progress, not efficacy results.

Completing enrollment in a Phase 2 study is an operational milestone that allows the trial to proceed toward data analysis. The study evaluates divesiran in polycythemia vera, a blood disorder.

The filing furnishes a press release (Exhibit 99.1) and does not provide clinical outcomes or timelines. Any impact will depend on subsequent data disclosures; this excerpt does not specify them.

truefalse0001479615X000-000000000014796152025-10-232025-10-230001479615us-gaap:CommonStockMember2025-10-232025-10-230001479615dei:AdrMember2025-10-232025-10-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2025

Silence Therapeutics plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales	001-39487	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
12 Hammersmith Grove London United Kingdom		W6 7AP
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share		SLN		The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per share*		*		The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 23, 2025, Silence Therapeutics plc issued a press release announcing completion of enrollment in the SANRECO Phase 2 study of divesiran for the treatment of polycythemia vera (PV). A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Exhibits.

(a)Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number		Description
99.1		Press Release dated October 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Company Name
Date: October 23, 2025		By:	/s/ Craig Tooman
			Name: Craig Tooman
			Title: President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did SLN announce in this 8-K?

Silence Therapeutics completed enrollment in the SANRECO Phase 2 study of divesiran for polycythemia vera (PV) and furnished a press release as Exhibit 99.1.

Which program reached a milestone for SLN?

The SANRECO Phase 2 study evaluating divesiran in polycythemia vera.

Is the press release part of the filing record?

It is furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.

Does the 8-K include clinical results or data for SLN?

No. It notes enrollment completion and furnishes a press release; it does not present efficacy or safety results.

What section of the 8-K covers this update for SLN?

The update is reported under Item 8.01 Other Events.

What exchange lists Silence Therapeutics' ADSs (SLN)?

The Nasdaq Stock Market LLC; each ADS represents 3 ordinary shares.